Optimizing Treatment for HR+/HER2- Breast Cancer: A Multidisciplinary Approach - Episode 10

Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer

September 19, 2023

Naomi Dempsey, MD, Nadia Nocera Zachariah, MD, Priya K Bhatt, APRN, Kush Kumar, PharmD

The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Importance of Multidisciplinary Care for Patients With HR+/HER- Breast Cancer

EP. 2: Barriers to Optimal Care in Patients With HR+/HER- Breast Cancer

EP. 3: Clinical Scenario: A 60-Year-Old Woman With Newly Diagnosed Breast Cancer

EP. 4: Considerations for Chemotherapy Dosing in Patients With HR+/HER- Breast Cancer

EP. 5: Helping Patients With HR+/HER2- Breast Cancer Access Abemaciclib

EP. 6: Updates in Adjuvant Therapy for HR+/HER- Breast Cancer From ASCO 2023: The NATALEE Trial

EP. 7: Monitoring and Treating Lymphedema in Patients With HR+/HER- Breast Cancer

EP. 8: Frontline CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

EP. 9: Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

Now Viewing

EP. 10: Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer

EP. 11: Utility of Primary Tumor Surgery for De Novo Metastatic Breast Cancer

EP. 12: Unmet Needs in the Treatment of HR+/HER2- Breast Cancer